Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents?

Current Medicinal Chemistry

Volumn 21, Issue 25, 2014, Pages 2927-2946

  Dragan, S ^a   Serban, C ^a   Banach, M ^b  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Dysfunctional HDL; HDL functionality; Reverse cholesterol transport

Indexed keywords

BIOLOGICAL MARKER; CAROTENOID; CATECHIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CURCUMIN; ELLAGIC ACID; EZETIMIBE; FARNESOID X RECEPTOR; GREEN TEA EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; KAEMPFEROL; LIPID; LIVER X RECEPTOR; LYCOPENE; MICRORNA; NICOTINIC ACID; OLIVE OIL; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYPHENOL; POMEGRANATE EXTRACT; PROTEIN; QUERCETIN; RESVERATROL; RNA; UNINDEXED DRUG; VITAMIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CACAO; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CIRCULATION; CORONARY ARTERY ATHEROSCLEROSIS; DIET; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIFESTYLE MODIFICATION; NONHUMAN; POMEGRANATE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TEA; UPREGULATION; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; RISK FACTOR;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; RISK FACTORS;

EID: 84906087005     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140303153829     Document Type: Article

References (239)

1. Go, A.S.; Mozaffarian, D.; Roger, V.L.; Benjamin, E.J.; Berry, J.D.; Borden, W.B.; Bravata, D.M.; Dai, S.; Ford, E.S.; Fox, C.S.; Franco, S.; Fullerton, H.J.; Gillespie, C.; Hailpern, S.M.; Heit, J.A.; Howard, V.J.; Huffman, M.D.; Kissela, B.M.; Kittner, S.J.; Lackland, D.T.; Lichtman, J.H.; Lisabeth, L.D.; Magid, D.; Marcus, G.M.; Marelli, A.; Matchar, D.B.; McGuire, D.K.; Mohler, E.R.; Moy, C.S.; Mussolino, M.E.; Nichol, G.; Paynter, N.P.; Schreiner, P.J.; Sorlie, P.D.; Stein, J.; Turan, T.N.; Virani, S.S.; Wong, N.D.; Woo, D.; Turner, M.B.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2014 Update: A Report From the American Heart Association. Circulation, 2013, 127(1), e6-e245.
2. Banach, M.; Aronow, W.S. Hypertension therapy in the older adults-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J. Human Hypertens., 2012, 26(11), 641-643.
3. Nichols, M.; Townsend, N.; Scarborough, P.; Rayner, M. Cardiovascular disease in Europe: epidemiological update. Eur. Heart J., 2013, 34(39), 3028-3034.
4. Barylski, M.; Mikhailidis, D.P.; Ciebiada, M.; Rysz, J.; Banach, M. Gender differences in the treatment of ischemic heart disease. Curr. Pharm. Des., 2011, 17(11), 1059-1069.
5. Liu, X.; Suo, R.; Xiong, S.L.; Zhang, Q.H.; Yi, G.H. HDL drug carriers for targeted therapy. Clin. Chim. Acta, 2013, 415, 94-100.
6. Eren, E.; Yilmaz, N.; Aydin, O. Functionally Defective High-Density Lipoprotein and Paraoxonase: A Couple for Endothelial Dysfunction in Atherosclerosis. Cholesterol, 2013, 2013, 792090.
7. Laufs, U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur. J. Clin. Pharmacol., 2003, 58(11), 719-731.
8. Mackey, R.H.; Greenland, P.; Goff, D.C., Jr.; Lloyd-Jones, D.; Sibley, C.T.; Mora, S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol., 2012, 60(6), 508-516.
9. El Harchaoui, K.; Arsenault, B.J.; Franssen, R.; Despres, J.P.; Hovingh, G.K.; Stroes, E.S.; Otvos, J.D.; Wareham, N.J.; Kastelein, J.J.; Khaw, K.T.; Boekholdt, S.M. High-density lipoprotein particle size and concentration and coronary risk. Ann. Intern. Med., 2009, 150(2), 84-93.
10. Stock, J. CETP inhibition in perspective. Atherosclerosis, 2012, 220(2), 325-328.
11. Burchardt, P.; Zurawski, J.; Zuchowski, B.; Kubacki, T.; Murawa, D.; Wiktorowicz, K.; Wysocki, H. Low-density lipoprotein, its susceptibility to oxidation and the role of lipoprotein-associated phospholipase A2 and carboxyl ester lipase lipases in atherosclerotic plaque formation. Arch. Med. Sci., 2013, 9(1), 151-158.
12. Rye, K.A.; Bursill, C.A.; Lambert, G.; Tabet, F.; Barter, P.J. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res., 2009, 50 Suppl, S195-S200.
13. Kontush, A.; Lhomme, M.; Chapman, M.J. Unraveling the complexities of the HDL lipidome. J. Lipid Res., 2013, 54(11), 2950-2963.
14. Marsche, G.; Saemann, M.D.; Heinemann, A.; Holzer, M. Inflammation alters HDL composition and function: implications for HDL-raising therapies. Pharmacol. Ther., 2013, 137(3), 341-351.
15. Annema, W.; von Eckardstein, A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ. J., 2013, 77(10), 2432-2448.
16. Otocka-Kmiecik, A.; Mikhailidis, D.P.; Nicholls, S.J.; Davidson, M.; Rysz, J.; Banach, M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog. Lipid Res., 2012, 51(4), 314-324.
17. Duffy, D.; Rader, D.J. Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol., 2009, 6(7), 455-463.
18. Degoma, E.M.; Rader, D.J. Novel HDL-directed pharmacotherapeutic strategies. Nat. Rev. Cardiol., 2011, 8(5), 266-277.
19. Mackness, B.; Turkie, W.; Mackness, M. Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease. Arch. Med. Sci., 2013, 9(1), 8-13.
20. Yilmaz, N. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Arch. Med. Sci., 2012, 8(1), 138-153.
21. Zheng, C.; Aikawa, M. High-density lipoproteins: from function to therapy. J. Am. Coll. Cardiol., 2012, 60(23), 2380-2383.
22. van Capelleveen, J.C.; Brewer, H.B.; Kastelein, J.J.; Hovingh, G.K. Novel therapies focused on the high-density lipoprotein particle. Circulation Res., 2014, 114(1), 193-204.
23. Joy, T.R. Novel HDL-based therapeutic agents. Pharmacol. Ther., 2012, 135(1), 18-30.
24. Khera, A.V.; Rader, D.J. Future therapeutic directions in reverse cholesterol transport. Curr. Atheroscl. Rep., 2010, 12(1), 73-81.
25. Barylski, M.; Nikolic, D.; Banach, M.; Toth, P.P.; Montalto, G.; Rizzo, M. Statins and New-Onset Diabetes. Curr. Pharm. Des., 2014, 20(22), 3657-3664.
26. Van Lenten, B.J.; Hama, S.Y.; de Beer, F.C.; Stafforini, D.M.; McIntyre, T.M.; Prescott, S.M.; La Du, B.N.; Fogelman, A.M.; Navab, M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest., 1995, 96(6), 2758-2767.
27. Heinecke, J.W. The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. J. Lipid Res., 2009, 50 Suppl., S167-S171.
28. Bacchetti, T.; Masciangelo, S.; Armeni, T.; Bicchiega, V.; Ferretti, G. Glycation of human high density lipoprotein by methylglyoxal: Effect on HDL-paraoxonase activity. Metabolism, 2014, 63(3), 307-311.
29. Eren, E.; Yilmaz, N.; Aydin, O. High Density Lipoprotein and it's Dysfunction. Open Biochem. J., 2012, 6, 78-93.
30. Monastiriotis, C.; Papanas, N.; Veletza, S.; Maltezos, E. APOE gene polymorphisms and diabetic peripheral neuropathy. Arch. Med. Sci., 2012, 8(4), 583-588.
31. Chyu, K.Y.; Peter, A.; Shah, P.K. Progress in HDL-based therapies for atherosclerosis. Curr. Atheroscl. Rep., 2011, 13(5), 405-412.
32. Eriksson, M.; Carlson, L.A.; Miettinen, T.A.; Angelin, B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation, 1999, 100(6), 594-598.
33. Kontush, A.; Guerin, M.; Chapman, M.J. Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nature clinical practice. Cardiovasc. Med., 2008, 5(6), 329-336.
34. Klon, A.E.; Jones, M.K.; Segrest, J.P.; Harvey, S.C. Molecular belt models for the apolipoprotein A-I Paris and Milano mutations. Biophys. J., 2000, 79(3), 1679-1685.
35. Tardif, J.C.; Gregoire, J.; L'Allier, P.L.; Ibrahim, R.; Lesperance, J.; Heinonen, T.M.; Kouz, S.; Berry, C.; Basser, R.; Lavoie, M.A.; Guertin, M.C.; Rodes-Cabau, J.; Effect of r, H.D.L.o.A.-S.; Efficacy, I. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA, 2007, 297(15), 1675-1682.
36. Hoang, A.; Drew, B.G.; Low, H.; Remaley, A.T.; Nestel, P.; Kingwell, B.A.; Sviridov, D. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur. Heart J., 2012, 33(5), 657-665.
37. Diditchenko, S.; Gille, A.; Pragst, I.; Stadler, D.; Waelchli, M.; Hamilton, R.; Leis, A.; Wright, S.D. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol., 2013, 33(9), 2202-2211.
38. de la Llera-Moya, M.; Drazul-Schrader, D.; Asztalos, B.F.; Cuchel, M.; Rader, D.J.; Rothblat, G.H. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol., 2010, 30(4), 796-801.
39. Tardy, C.; Goffinet, M.; Boubekeur, N.; Ackermann, R.; Sy, G.; Bluteau, A.; Cholez, G.; Keyserling, C.; Lalwani, N.; Paolini, J.F.; Dasseux, J.L.; Barbaras, R.; Baron, R. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis, 2014, 232(1), 110-118.
40. Perez-Mendez, O.; Bruckert, E.; Franceschini, G.; Duhal, N.; Lacroix, B.; Bonte, J.P.; Sirtori, C.; Fruchart, J.C.; Turpin, G.; Luc, G. Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. Atherosclerosis, 2000, 148(2), 317-325.
41. Sirtori, C.R.; Calabresi, L.; Franceschini, G.; Baldassarre, D.; Amato, M.; Johansson, J.; Salvetti, M.; Monteduro, C.; Zulli, R.; Muiesan, M.L.; Agabiti-Rosei, E. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation, 2001, 103(15), 1949-1954.
42. Shah, P.K.; Yano, J.; Reyes, O.; Chyu, K.Y.; Kaul, S.; Bisgaier, C.L.; Drake, S.; Cercek, B. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation, 2001, 103(25), 3047-3050.
43. Nissen, S.E.; Tsunoda, T.; Tuzcu, E.M.; Schoenhagen, P.; Cooper, C.J.; Yasin, M.; Eaton, G.M.; Lauer, M.A.; Sheldon, W.S.; Grines, C.L.; Halpern, S.; Crowe, T.; Blankenship, J.C.; Kerensky, R. C.L.; Halpern, S.; Crowe, T.; Blankenship, J.C.; Kerensky, R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA, 2003, 290(17), 2292-2300.
44. Nicholls, S.J.; Uno, K.; Kataoka, Y.; Nissen, S.E. ETC-216 for coronary artery disease. Expert Opin. Biol. Ther., 2011, 11(3), 387-394.
45. Dimayuga, P.; Zhu, J.; Oguchi, S.; Chyu, K.Y.; Xu, X.O.; Yano, J.; Shah, P.K.; Nilsson, J.; Cercek, B. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem. Biophys. Res. Commun., 1999, 264(2), 465-468.
46. Waksman, R.; Torguson, R.; Kent, K.M.; Pichard, A.D.; Suddath, W.O.; Satler, L.F.; Martin, B.D.; Perlman, T.J.; Maltais, J.A.; Weissman, N.J.; Fitzgerald, P.J.; Brewer, H.B., Jr. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J. Am. Coll. Cardiol., 2010, 55(24), 2727-2735.
47. McLure, K.G.; Gesner, E.M.; Tsujikawa, L.; Kharenko, O.A.; Attwell, S.; Campeau, E.; Wasiak, S.; Stein, A.; White, A.; Fontano, E.; Suto, R.K.; Wong, N.C.; Wagner, G.S.; Hansen, H.C.; Young, P.R. RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist. PloS One, 2013, 8(12), e83190.
48. McNeill, E. RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases. Current Opin. Investig. Drugs, 2010, 11(3), 357-364.
49. Di Bartolo, B.A.; Vanags, L.Z.; Tan, J.T.; Bao, S.; Rye, K.A.; Barter, P.J.; Bursill, C.A. The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit. Lipid. Health Dis., 2011, 10, 224.
50. Pal, M.; Pillarisetti, S. HDL elevators and mimetics-emerging therapies for atherosclerosis. Cardiovasc. Hematol. Agent. Med Chem., 2007, 5(1), 55-66.
51. Navab, M.; Shechter, I.; Anantharamaiah, G.M.; Reddy, S.T.; Van Lenten, B.J.; Fogelman, A.M. Structure and function of HDL mimetics. Arterioscler. Thromb. Vasc. Biol., 2010, 30(2), 164-168.
52. Getz, G.S.; Reardon, C.A., Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis. Journal of inflammation research, 2011, 4, 83-92.
53. Uehara, Y.; Ando, S.; Yahiro, E.; Oniki, K.; Ayaori, M.; Abe, S.; Kawachi, E.; Zhang, B.; Shioi, S.; Tanigawa, H.; Imaizumi, S.; Miura, S.; Saku, K. FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in ApoE-deficient mice. J. Am. Heart Assoc., 2013, 2(3), e000048.
54. Chroni, A.; Liu, T.; Gorshkova, I.; Kan, H.Y.; Uehara, Y.; Von Eckardstein, A.; Zannis, V.I. The central helices of ApoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type ApoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo. J. Biol. Chem., 2003, 278(9), 6719-6730.
55. Ditiatkovski, M.; D'Souza, W.; Kesani, R.; Chin-Dusting, J.; de Haan, J.B.; Remaley, A.; Sviridov, D. An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. PloS One, 2013, 8(7), e68802.
56. Bielicki, J.K.; Zhang, H.; Cortez, Y.; Zheng, Y.; Narayanaswami, V.; Patel, A.; Johansson, J.; Azhar, S. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J. Lipid Res., 2010, 51(6), 1496-1503.
57. Amar, M.J.; D'Souza, W.; Turner, S.; Demosky, S.; Sviridov, D.; Stonik, J.; Luchoomun, J.; Voogt, J.; Hellerstein, M.; Sviridov, D.; Remaley, A.T. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J. Pharm. Exp. Ther., 2010, 334(2), 634-641.
58. Sviridov, D.O.; Andrianov, A.M.; Anishchenko, I.V.; Stonik, J.A.; Amar, M.J.; Turner, S.; Remaley, A.T. Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter. J. Pharm. Exp. Ther., 2013, 344(1), 50-58.
59. Tabet, F.; Remaley, A.T.; Segaliny, A.I.; Millet, J.; Yan, L.; Nakhla, S.; Barter, P.J.; Rye, K.A.; Lambert, G. The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler. Thromb. Vasc. Biol., 2010, 30(2), 246-252.
60. Du, L.; Qu, X.; Zheng, H.; Li, R.; Wang, J.; Chen, M.; Zhao, P.; Zhang, Z.; Gong, K. Reverse apolipoprotein A-I mimetic peptide R-D4F inhibits neointimal formation following carotid artery ligation in mice. Am. J. Pathol., 2013, 182(5), 1932-1939.
61. Navab, M.; Reddy, S.T.; Anantharamaiah, G.M.; Imaizumi, S.; Hough, G.; Hama, S.; Fogelman, A.M. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J. Lipid Res., 2011, 52(6), 1200-1210.
62. Smith, J.D. Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr. Opin. Invest. Drug, 2010, 11(9), 989-996.
63. Imaizumi, S.; Navab, M.; Morgantini, C.; Charles-Schoeman, C.; Su, F.; Gao, F.; Kwon, M.; Ganapathy, E.; Meriwether, D.; Farias-Eisner, R.; Fogelman, A.M.; Reddy, S.T. Dysfunctional highdensity lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circ. J., 2011, 75(7), 1533-1538.
64. Bloedon, L.T.; Dunbar, R.; Duffy, D.; Pinell-Salles, P.; Norris, R.; DeGroot, B.J.; Movva, R.; Navab, M.; Fogelman, A.M.; Rader, D.J. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res., 2008, 49(6), 1344-1352.
65. Watson, C.E.; Weissbach, N.; Kjems, L.; Ayalasomayajula, S.; Zhang, Y.; Chang, I.; Navab, M.; Hama, S.; Hough, G.; Reddy, S.T.; Soffer, D.; Rader, D.J.; Fogelman, A.M.; Schecter, A. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res., 2011, 52(2), 361-373.
66. Navab, M.; Reddy, S.T.; Van Lenten, B.J.; Fogelman, A.M. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol., 2011, 8(4), 222-232.
67. Maiga, S.F.; Kalopissis, A.D.; Chabert, M. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes. Biochimie, 2014, 96, 56-66.
68. Zheng, C.; Azcutia, V.; Aikawa, E.; Figueiredo, J.L.; Croce, K.; Sonoki, H.; Sacks, F.M.; Luscinskas, F.W.; Aikawa, M. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur. Heart J., 2013, 34(8), 615-624.
69. Sacks, F.M.; Zheng, C.; Cohn, J.S. Complexities of plasma apolipoprotein C-III metabolism. J. Lipid Res., 2011, 52(6), 1067-1070.
70. Kypreos, K.E.; Zannis, V.I. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem. J., 2007, 403(2), 359-367.
71. Kypreos, K.E. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia. Biochemistry, 2008, 47(39), 10491-10502.
72. Riwanto, M.; Rohrer, L.; Roschitzki, B.; Besler, C.; Mocharla, P.; Mueller, M.; Perisa, D.; Heinrich, K.; Altwegg, L.; von Eckardstein, A.; Luscher, T.F.; Landmesser, U. Altered activation of endothelial anti-and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of highdensity lipoprotein-proteome remodeling. Circulation, 2013, 127(8), 891-904.
73. Jensen, M.K.; Rimm, E.B.; Furtado, J.D.; Sacks, F.M. Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. J. Am. Heart Assoc., 2012, 1(2), pii: jah3-e000232. doi: 10.1161/JAHA.111.000232.
74. Zhao, W.; Du, F.; Zhang, M.; Sun, S.; Yu, H.; Fan, D. A new recombinant human apolipoprotein E mimetic peptide with highdensity lipoprotein binding and function enhancing activity. Exp. Biol. Med., 2011, 236(12), 1468-1476.
75. Zhao, Y.; Imura, T.; Leman, L.J.; Curtiss, L.K.; Maryanoff, B.E.; Ghadiri, M.R. Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs. J. Am. Chem. Soc., 2013, 135(36), 13414-13424.
76. Verdier, C.; Martinez, L.O.; Ferrieres, J.; Elbaz, M.; Genoux, A.; Perret, B. Targeting high-density lipoproteins: Update on a promising therapy. Arch. Cardiovasc. Dis., 2013, 106(11), 601-611.
77. Berge, K.G.; Canner, P.L. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur. J. Clin. Pharmacol., 1991, 40 Suppl 1, S49-S51.
78. Khera, A.V.; Patel, P.J.; Reilly, M.P.; Rader, D.J. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J. Am. Coll. Cardiol., 2013, 62(20), 1909-1910.
79. Yvan-Charvet, L.; Kling, J.; Pagler, T.; Li, H.; Hubbard, B.; Fisher, T.; Sparrow, C.P.; Taggart, A.K.; Tall, A.R. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol., 2010, 30(7), 1430-1438.
80. Investigators, A.-H.; Boden, W.E.; Probstfield, J.L.; Anderson, T.; Chaitman, B.R.; Desvignes-Nickens, P.; Koprowicz, K.; McBride, R.; Teo, K.; Weintraub, W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New Engl. J. Med., 2011, 365(24), 2255-2267.
81. Group, H.T.C. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J., 2013, 34(17), 1279-1291.
82. Lauring, B.; Taggart, A.K.; Tata, J.R.; Dunbar, R.; Caro, L.; Cheng, K.; Chin, J.; Colletti, S.L.; Cote, J.; Khalilieh, S.; Liu, J.; Luo, W.L.; Maclean, A.A.; Peterson, L.B.; Polis, A.B.; Sirah, W.; Wu, T.J.; Liu, X.; Jin, L.; Wu, K.; Boatman, P.D.; Semple, G.; Behan, D.P.; Connolly, D.T.; Lai, E.; Wagner, J.A.; Wright, S.D.; Cuffie, C.; Mitchel, Y.B.; Rader, D.J.; Paolini, J.F.; Waters, M.G.; Plump, A. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci. Transl. Med., 2012, 4(148), 148ra115.
83. von Eckardstein, A.; Nofer, J.R.; Assmann, G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol., 2001, 21(1), 13-27.
84. Bellanger, N.; Julia, Z.; Villard, E.F.; El Khoury, P.; Duchene, E.; Chapman, M.J.; Fournier, N.; Le Goff, W.; Guerin, M. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Atherosclerosis, 2012, 221(1), 160-168.
85. Brousseau, M.E.; Schaefer, E.J.; Wolfe, M.L.; Bloedon, L.T.; Digenio, A.G.; Clark, R.W.; Mancuso, J.P.; Rader, D.J. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. New Engl. J. Med., 2004, 350(15), 1505-1515.
86. Arsenault, B.J.; Boekholdt, S.M.; Tardif, J.C.; Kastelein, J.J. Derisking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough? Eur. Heart J., 2012, 33(13), 1548-1550.
87. Mohammadpour, A.H.; Akhlaghi, F. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin. Pharmacokinetics, 2013, 52(8), 615-626.
88. Fayad, Z.A.; Mani, V.; Woodward, M.; Kallend, D.; Abt, M.; Burgess, T.; Fuster, V.; Ballantyne, C.M.; Stein, E.A.; Tardif, J.C.; Rudd, J.H.; Farkouh, M.E.; Tawakol, A.; dal, P.I. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel noninvasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet, 2011, 378(9802), 1547-1559.
89. Cannon, C.P.; Dansky, H.M.; Davidson, M.; Gotto, A.M., Jr.; Brinton, E.A.; Gould, A.L.; Stepanavage, M.; Liu, S.X.; Shah, S.; Rubino, J.; Gibbons, P.; Hermanowski-Vosatka, A.; Binkowitz, B.; Mitchel, Y.; Barter, P.; investigators, D. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am. Heart J., 2009, 158(4), 513-519 e513.
90. Symposium: High Density Lipoproteins (HDL). Structure, function, analysis, clinical, epidemiological and metabolic aspects of HDL. AOCS Annual Meeting, St. Louis, Missouri -May 15, 16, 1978. Lipids, 1979, 14, (1), 90-125.
91. Niesor, E.J.; Magg, C.; Ogawa, N.; Okamoto, H.; von der Mark, E.; Matile, H.; Schmid, G.; Clerc, R.G.; Chaput, E.; Blum-Kaelin, D.; Huber, W.; Thoma, R.; Pflieger, P.; Kakutani, M.; Takahashi, D.; Dernick, G.; Maugeais, C., Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J. Lipid Res., 2010, 51(12), 3443-3454.
92. Wang, S.P.; Daniels, E.; Chen, Y.; Castro-Perez, J.; Zhou, H.; Akinsanya, K.O.; Previs, S.F.; Roddy, T.P.; Johns, D.G. In vivo effects of anacetrapib on prebeta HDL: improvement in HDL remodeling without effects on cholesterol absorption. J. Lipid Res., 2013, 54(10), 2858-2865.
93. Cao, G.; Beyer, T.P.; Zhang, Y.; Schmidt, R.J.; Chen, Y.Q.; Cockerham, S.L.; Zimmerman, K.M.; Karathanasis, S.K.; Cannady, E.A.; Fields, T.; Mantlo, N.B. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J. Lipid Res., 2011, 52(12), 2169-2176.
94. Pedersen, T.R.; Kjekshus, J.; Berg, K.; Haghfelt, T.; Faergeman, O.; Faergeman, G.; Pyorala, K.; Miettinen, T.; Wilhelmsen, L.; Olsson, A.G.; Wedel, H.; Scandinavian Simvastatin Survival Study, G. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis. Suppl., 2004, 5(3), 81-87.
95. Oida, K. [CARE[ Cholesterol and Recurrent Events Trial]]. Jpn. J. Clin. Med., 2001, 59 Suppl 3, 427-432.
96. Grundy, S.M. Statin trials and goals of cholesterol-lowering therapy. Circulation, 1998, 97(15), 1436-1439.
97. McEvoy, J.W.; Margey, R.; Blake, G.J. Long-term follow-up of the West of Scotland Coronary Prevention Study. New Engl. J. Med., 2008, 358(2), 193; author reply 194-195.
98. Sattar, N.; Preiss, D.; Murray, H.M.; Welsh, P.; Buckley, B.M.; de Craen, A.J.; Seshasai, S.R.; McMurray, J.J.; Freeman, D.J.; Jukema, J.W.; Macfarlane, P.W.; Packard, C.J.; Stott, D.J.; Westendorp, R.G.; Shepherd, J.; Davis, B.R.; Pressel, S.L.; Marchioli, R.; Marfisi, R.M.; Maggioni, A.P.; Tavazzi, L.; Tognoni, G.; Kjekshus, J.; Pedersen, T.R.; Cook, T.J.; Gotto, A.M.; Clearfield, M.B.; Downs, J.R.; Nakamura, H.; Ohashi, Y.; Mizuno, K.; Ray, K.K.; Ford, I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 2010, 375(9716), 735-742.
99. Barylski, M.; Malyszko, J.; Rysz, J.; Mysliwiec, M.; Banach, M. Lipids, blood pressure, kidney -what was new in 2011? Arch. Med. Sci., 2011, 7(6), 1055-1066.
100. Sviridov, D.; Nestel, P.; Watts, G. Statins and metabolism of high density lipoprotein. Cardiovasc. Hematol. Agent. Med. Chem., 2007, 5(3), 215-221.
101. Jafri, H.; Alsheikh-Ali, A.A.; Karas, R.H. Meta-analysis: statin therapy does not alter the association between low levels of highdensity lipoprotein cholesterol and increased cardiovascular risk. Ann. Intern. Med., 2010, 153(12), 800-808.
102. Posadas-Sanchez, R.; Posadas-Romero, C.; Mendoza-Perez, E.; Caracas-Portilla, N.A.; Cardoso-Saldana, G.; Medina-Urrutia, A.; Jorge-Galarza, E.; Juarez-Rojas, J.G. Cholesterol efflux and metabolic abnormalities associated with low high-densitylipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl. Am. J. Cardiol., 2012, 109(5), 636-641.
103. HDL function, not just amount, could affect artery health. Harv. Heart Lett., 2011, 21(9), 7.
104. Kowalski, J.; Barylski, M.; Banach, M.; Grycewicz, J.; Irzmanski, R.; Pawlicki, L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J. Cardiovasc. Pharmacol., 2006, 48(4), 143-147.
105. Zhou, Q.; Liao, J.K. Pleiotropic effects of statins. -Basic research and clinical perspectives. Circ. J., 2010, 74(5), 818-826.
106. Huang, C.Y.; Lin, F.Y.; Shih, C.M.; Au, H.K.; Chang, Y.J.; Nakagami, H.; Morishita, R.; Chang, N.C.; Shyu, K.G.; Chen, J.W. Moderate to high concentrations of high-density lipoprotein from healthy subjects paradoxically impair human endothelial progenitor cells and related angiogenesis by activating Rho-associated kinase pathways. Arterioscler. Thromb. Vasc. Biol., 2012, 32(10), 2405-2417.
107. Khera, A.V.; Cuchel, M.; de la Llera-Moya, M.; Rodrigues, A.; Burke, M.F.; Jafri, K.; French, B.C.; Phillips, J.A.; Mucksavage, M.L.; Wilensky, R.L.; Mohler, E.R.; Rothblat, G.H.; Rader, D.J. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. New Engl. J. Med., 2011, 364(2), 127-135.
108. Yagyu, H.; Nagashima, S.; Takahashi, M.; Miyamoto, M.; Okada, K.; Osuga, J.; Ishibashi, S. Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesteryl ester transfer protein in type 2 diabetes mellitus. Endocrine J., 2012, 59(12), 1077-1084.
109. Xie, P.; Jia, L.; Ma, Y.; Ou, J.; Miao, H.; Wang, N.; Guo, F.; Yazdanyar, A.; Jiang, X.C.; Yu, L. Ezetimibe inhibits hepatic Niemann-Pick C1-Like 1 to facilitate macrophage reverse cholesterol transport in mice. Arterioscler. Thromb. Vasc. Biol., 2013, 33(5), 920-925.
110. Maugeais, C.; Annema, W.; Blum, D.; Mary, J.L.; Tietge, U.J. rHDL administration increases reverse cholesterol transport in mice, but is not additive on top of ezetimibe or cholestyramine treatment. Atherosclerosis, 2013, 229(1), 94-101.
111. Nakou, E.S.; Filippatos, T.D.; Kiortsis, D.N.; Derdemezis, C.S.; Tselepis, A.D.; Mikhailidis, D.P.; Elisaf, M.S. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Exp. Opin. Pharmacother., 2008, 9(18), 3151-3158.
112. Filippatos, T.D.; Kiortsis, D.N.; Liberopoulos, E.N.; Georgoula, M.; Mikhailidis, D.P.; Elisaf, M.S. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr. Med. Res. Opin., 2005, 21(12), 1997-2006.
113. Bartel, D.P. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136(2), 215-233.
114. Shukla, G.C.; Singh, J.; Barik, S. MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol. Cell. Pharmacol., 2011, 3(3), 83-92.
115. Rayner, K.J.; Moore, K.J. MicroRNA Control of High-Density Lipoprotein Metabolism and Function. Circulation Res., 2014, 114(1), 183-192.
116. Rayner, K.J.; Esau, C.C.; Hussain, F.N.; McDaniel, A.L.; Marshall, S.M.; van Gils, J.M.; Ray, T.D.; Sheedy, F.J.; Goedeke, L.; Liu, X.; Khatsenko, O.G.; Kaimal, V.; Lees, C.J.; Fernandez-Hernando, C.; Fisher, E.A.; Temel, R.E.; Moore, K.J. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature, 2011, 478(7369), 404-407.
117. Ouimet, M.; Moore, K.J. A big role for small RNAs in HDL homeostasis. J. Lipid Res., 2013, 54, (5), 1161-1167.
118. Moore, K.J., microRNAs: small regulators with a big impact on lipid metabolism. J. Lipid Res., 2013, 54(5), 1159-1160.
119. Rayner, K.J.; Suarez, Y.; Davalos, A.; Parathath, S.; Fitzgerald, M.L.; Tamehiro, N.; Fisher, E.A.; Moore, K.J.; Fernandez-Hernando, C. MiR-33 contributes to the regulation of cholesterol homeostasis. Science, 2010, 328(5985), 1570-1573.
120. Rotllan, N.; Ramirez, C.M.; Aryal, B.; Esau, C.C.; Fernandez-Hernando, C. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/-mice-brief report. Arterioscler. Thromb. Vasc. Biol., 2013, 33(8), 1973-1977.
121. Marquart, T.J.; Wu, J.; Lusis, A.J.; Baldan, A. Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2013, 33(3), 455-458.
122. Sun, X.; He, S.; Wara, A.K.; Icli, B.; Shvartz, E.; Tesmenitsky, Y.; Belkin, N.; Li, D.; Blackwell, T.S.; Sukhova, G.K.; Croce, K.; Feinberg, M.W. Systemic Delivery of MicroRNA-181b Inhibits Nuclear Factor-kappaB Activation, Vascular Inflammation, and Atherosclerosis in Apolipoprotein E-Deficient Mice. Circulation Res., 2014, 114(1), 32-40.
123. Chen, H.; Yang, J.; Zhang, Q.; Chen, L.H.; Wang, Q. Corosolic acid ameliorates atherosclerosis in apolipoprotein E-deficient mice by regulating the nuclear factor-kappaB signaling pathway and inhibiting monocyte chemoattractant protein-1 expression. Circ. J., 2012, 76(4), 995-1003.
124. Repa, J.J.; Turley, S.D.; Lobaccaro, J.A.; Medina, J.; Li, L.; Lustig, K.; Shan, B.; Heyman, R.A.; Dietschy, J.M.; Mangelsdorf, D.J. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science, 2000, 289(5484), 1524-1529.
125. Repa, J.J.; Mangelsdorf, D.J. The liver X receptor gene team: potential new players in atherosclerosis. Nat. Med., 2002, 8(11), 1243-1248.
126. Brunham, L.R.; Kruit, J.K.; Iqbal, J.; Fievet, C.; Timmins, J.M.; Pape, T.D.; Coburn, B.A.; Bissada, N.; Staels, B.; Groen, A.K.; Hussain, M.M.; Parks, J.S.; Kuipers, F.; Hayden, M.R. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest., 2006, 116(4), 1052-1062.
127. Costet, P.; Luo, Y.; Wang, N.; Tall, A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem., 2000, 275(36), 28240-28245.
128. Rigamonti, E.; Helin, L.; Lestavel, S.; Mutka, A.L.; Lepore, M.; Fontaine, C.; Bouhlel, M.A.; Bultel, S.; Fruchart, J.C.; Ikonen, E.; Clavey, V.; Staels, B.; Chinetti-Gbaguidi, G. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circulation Res., 2005, 97(7), 682-689.
129. Oosterveer, M.H.; Grefhorst, A.; Groen, A.K.; Kuipers, F. The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design. Prog. Lipid Res., 2010, 49(4), 343-352.
130. Zhou, J.; Febbraio, M.; Wada, T.; Zhai, Y.; Kuruba, R.; He, J.; Lee, J.H.; Khadem, S.; Ren, S.; Li, S.; Silverstein, R.L.; Xie, W. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology, 2008, 134(2), 556-567.
131. Shimomura, I.; Shimano, H.; Korn, B.S.; Bashmakov, Y.; Horton, J.D. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J. Biol. Chem., 1998, 273(52), 35299-35306.
132. Quinet, E.M.; Basso, M.D.; Halpern, A.R.; Yates, D.W.; Steffan, R.J.; Clerin, V.; Resmini, C.; Keith, J.C.; Berrodin, T.J.; Feingold, I.; Zhong, W.; Hartman, H.B.; Evans, M.J.; Gardell, S.J.; DiBlasio-Smith, E.; Mounts, W.M.; LaVallie, E.R.; Wrobel, J.; Nambi, P.; Vlasuk, G.P. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J. Lipid Res., 2009, 50(12), 2358-2370.
133. Terasaka, N.; Hiroshima, A.; Koieyama, T.; Ubukata, N.; Morikawa, Y.; Nakai, D.; Inaba, T. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett., 2003, 536(1-3), 6-11.
134. Joseph, S.B.; McKilligin, E.; Pei, L.; Watson, M.A.; Collins, A.R.; Laffitte, B.A.; Chen, M.; Noh, G.; Goodman, J.; Hagger, G.N.; Tran, J.; Tippin,
135. Mencarelli, A.; Fiorucci, S. FXR an emerging therapeutic target for the treatment of atherosclerosis. J. Cell. Mol. Med., 2010, 14(1-2), 79-92.
136. Fiorucci, S.; Cipriani, S.; Baldelli, F.; Mencarelli, A. Bile acidactivated receptors in the treatment of dyslipidemia and related disorders. Prog. Lipid Res., 2010, 49(2), 171-185.
137. Kim, T.; Yang, Q. Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system. World J. Cardiol., 2013, 5(6), 164-174.
138. Katsiki, N.; Nikolic, D.; Montalto, G.; Banach, M.; Mikhailidis, D.P.; Rizzo, M. The role of fibrate treatment in dyslipidemia: an overview. Curr. Pharm. Des., 2013, 19(17), 3124-3131.
139. Mukherjee, R.; Jow, L.; Croston, G.E.; Paterniti, J.R., Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem., 1997, 272(12), 8071-8076.
140. Ehrenborg, E.; Skogsberg, J. Peroxisome proliferator-activated receptor delta and cardiovascular disease. Atherosclerosis, 2013, 231(1), 95-106.
141. Mansour, M. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. Prog. Mol. Biol. Transl. Sci., 2014, 121, 217-266.
142. Bays, H.E.; Schwartz, S.; Littlejohn, T., 3rd; Kerzner, B.; Krauss, R.M.; Karpf, D.B.; Choi, Y.J.; Wang, X.; Naim, S.; Roberts, B.K. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J. Clin. Endocrinol. Metab., 2011, 96(9), 2889-2897.
143. Fruchart, J.C. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc. Diabetol., 2013, 12, 82.
144. Millar, J.S. Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk. Curr. Opin. Lipidol., 2013, 24(3), 233-238.
145. Lin, Q.; Jia, L.; Sun, Y. A pilot study of circulating PPAR-gamma receptor protein in elderly patients with atrial fibrillation. Arch. Med. Sci., 2012, 8(3), 471-476.
146. Pirillo, A.; Norata, G.D.; Catapano, A.L. High-density lipoprotein subfractions-what the clinicians need to know. Cardiology, 2013, 124(2), 116-125.
147. Norata, G.D.; Pirillo, A.; Catapano, A.L. Modified HDL: biological and physiopathological consequences. Nutr. Metab. Cardiovasc. Dis., 2006, 16(5), 371-386.
148. Goodman, K.B.; Bury, M.J.; Cheung, M.; Cichy-Knight, M.A.; Dowdell, S.E.; Dunn, A.K.; Lee, D.; Lieby, J.A.; Moore, M.L.; Scherzer, D.A.; Sha, D.; Suarez, D.P.; Murphy, D.J.; Harpel, M.R.; Manas, E.S.; McNulty, D.E.; Annan, R.S.; Matico, R.E.; Schwartz, B.K.; Trill, J.J.; Sweitzer, T.D.; Wang, D.Y.; Keller, P.M.; Krawiec, J.A.; Jaye, M.C. Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(1), 27-30.
149. O'Connell, D.P.; LeBlanc, D.F.; Cromley, D.; Billheimer, J.; Rader, D.J.; Bachovchin, W.W. Design and synthesis of boronic acid inhibitors of endothelial lipase. Bioorg. Med. Chem. Lett., 2012, 22(3), 1397-1401.
150. Banach, M.; Serban, C.; Aronow, W.S.; Rysz, J.; Dragan, S.; Lerma, E.V.; Apetrii, M.; Covic, A. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol. 2014, 46(5), 947-961.
151. Ferretti, G.; Bacchetti, T.; Busni, D.; Rabini, R.A.; Curatola, G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J. Clin. Endocrinol. Metab., 2004, 89(6), 2957-2962.
152. Gugliucci, A. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo. Clin. Chim. Acta, 2013, 429C, 38-45.
153. Gluba, A.; Pietrucha, T.; Banach, M.; Piotrowski, G.; Rysz, J. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology, 2010, 61(2), 157-165.
154. Gluba, A.; Banach, M.; Mikhailidis, D.P.; Rysz, J. Genetic determinants of cardiovascular disease: the renin-angiotensinaldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. In vivo, 2009, 23(5), 797-812.
155. Katz, P.M.; Leiter, L.A. Drugs targeting high-density lipoprotein cholesterol for coronary artery disease management. Can. J. Cardiol., 2012, 28(6), 667-677.
156. Chantepie, S.; Bochem, A.E.; Chapman, M.J.; Hovingh, G.K.; Kontush, A. High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity. PloS One, 2012, 7(11), e49336.
157. Meuwese, M.C.; Stroes, E.S.; Hazen, S.L.; van Miert, J.N.; Kuivenhoven, J.A.; Schaub, R.G.; Wareham, N.J.; Luben, R.; Kastelein, J.J.; Khaw, K.T.; Boekholdt, S.M. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol., 2007, 50(2), 159-165.
158. Shao, B.; Oda, M.N.; Oram, J.F.; Heinecke, J.W. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr. Opin. Cardiol., 2006, 21(4), 322-328.
159. Huang, Y.; Wu, Z.; Riwanto, M.; Gao, S.; Levison, B.S.; Gu, X.; Fu, X.; Wagner, M.A.; Besler, C.; Gerstenecker, G.; Zhang, R.; Li, X.M.; DiDonato, A.J.; Gogonea, V.; Tang, W.H.; Smith, J.D.; Plow, E.F.; Fox, P.L.; Shih, D.M.; Lusis, A.J.; Fisher, E.A.; DiDonato, J.A.; Landmesser, U.; Hazen, S.L. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J. Clin. Invest., 2013, 123(9), 3815-3828.
160. Pirillo, A.; Uboldi, P.; Bolego, C.; Kuhn, H.; Catapano, A.L. The 15-lipoxygenase-modified high density lipoproteins 3 fail to inhibit the TNF-alpha-induced inflammatory response in human endothelial cells. J. Immunol., 2008, 181(4), 2821-2830.
161. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Van Lenten, B.J.; Datta, G.; Garber, D.; Fogelman, A.M. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr. Opin. Lipidol., 2004, 15(6), 645-649.
162. Watson, A.D.; Navab, M.; Hama, S.Y.; Sevanian, A.; Prescott, S.M.; Stafforini, D.M.; McIntyre, T.M.; Du, B.N.; Fogelman, A.M.; Berliner, J.A. Effect of platelet activating factoracetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest., 1995, 95(2), 774-782.
163. Wang, Z.; Li, S.; Sun, L.; Fan, J.; Liu, Z. Comparative analyses of lipoprotein lipase, hepatic lipase, and endothelial lipase, and their binding properties with known inhibitors. PloS One, 2013, 8(8), e72146.
164. Tatematsu, S.; Francis, S.A.; Natarajan, P.; Rader, D.J.; Saghatelian, A.; Brown, J.D.; Michel, T.; Plutzky, J. Endothelial lipase is a critical determinant of high-density lipoproteinstimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium. Arterioscler. Thromb. Vasc. Biol., 2013, 33(8), 1788-1794.
165. McCoy, M.G.; Sun, G.S.; Marchadier, D.; Maugeais, C.; Glick, J.M.; Rader, D.J. Characterization of the lipolytic activity of endothelial lipase. J. Lipid Res., 2002, 43(6), 921-929.
166. Robert, J.; Lehner, M.; Frank, S.; Perisa, D.; von Eckardstein, A.; Rohrer, L. Interleukin 6 stimulates endothelial binding and transport of high-density lipoprotein through induction of endothelial lipase. Arterioscler. Thromb. Vasc. Biol., 2013, 33(12), 2699-2706.
167. Nijstad, N.; Wiersma, H.; Gautier, T.; van der Giet, M.; Maugeais, C.; Tietge, U.J. Scavenger receptor BI-mediated selective uptake is required for the remodeling of high density lipoprotein by endothelial lipase. J. Biol. Chem., 2009, 284(10), 6093-6100.
168. Jin, W.; Sun, G.S.; Marchadier, D.; Octtaviani, E.; Glick, J.M.; Rader, D.J. Endothelial cells secrete triglyceride lipase and phospholipase activities in response to cytokines as a result of endothelial lipase. Circulation Res., 2003, 92(6), 644-650.
169. Andersen, C.J.; Fernandez, M.L. Dietary approaches to improving atheroprotective HDL functions. Food Funct., 2013, 4(9), 1304-1313.
170. Smith, J.D. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler. Thromb. Vasc. Biol., 2010, 30(2), 151-155.
171. Navab, M.; Ananthramaiah, G.M.; Reddy, S.T.; Van Lenten, B.J.; Ansell, B.J.; Fonarow, G.C.; Vahabzadeh, K.; Hama, S.; Hough, G.; Kamranpour, N.; Berliner, J.A.; Lusis, A.J.; Fogelman, A.M. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res., 2004, 45(6), 993-1007.
172. Borriello, A.; Bencivenga, D.; Caldarelli, I.; Tramontano, A.; Borgia, A.; Zappia, V.; Della Ragione, F. Resveratrol: from basic studies to bedside. Cancer Treat. Res., 2014, 159, 167-184.
173. Iriti, M.; Faoro, F. Bioactivity of grape chemicals for human health. Nat. Prod. Commun., 2009, 4(5), 611-634.
174. Higdon, J.V.; Frei, B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit. Rev. Food Sci. Nutr., 2003, 43(1), 89-143.
175. Perez-Jimenez, J.; Neveu, V.; Vos, F.; Scalbert, A. Systematic analysis of the content of 502 polyphenols in 452 foods and beverages: an application of the phenol-explorer database. J. Agric. Food Chem., 2010, 58(8), 4959-4969.
176. D'Archivio, M.; Filesi, C.; Di Benedetto, R.; Gargiulo, R.; Giovannini, C.; Masella, R. Polyphenols, dietary sources and bioavailability. Ann. Ist. Super Sanita., 2007, 43(4), 348-361.
177. D'Archivio, M.; Filesi, C.; Vari, R.; Scazzocchio, B.; Masella, R. Bioavailability of the polyphenols: status and controversies. Int. J. Mol. Sci., 2010, 11(4), 1321-1342.
178. Michalska, M.; Gluba, A.; Mikhailidis, D.P.; Nowak, P.; Bielecka-Dabrowa, A.; Rysz, J.; Banach, M. The role of polyphenols in cardiovascular disease. Med. Sci. Monit., 2010, 16(5), RA110-119.
179. Milenkovic, D.; Deval, C.; Gouranton, E.; Landrier, J.F.; Scalbert, A.; Morand, C.; Mazur, A. Modulation of miRNA expression by dietary polyphenols in apoE deficient mice: a new mechanism of the action of polyphenols. PloS One, 2012, 7(1), e29837.
180. Costa, L.G.; Vitalone, A.; Cole, T.B.; Furlong, C.E. Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol., 2005, 69(4), 541-550.
181. Kiyici, A.; Okudan, N.; Gokbel, H.; Belviranli, M. The effect of grape seed extracts on serum paraoxonase activities in streptozotocin-induced diabetic rats. J. Med. Food, 2010, 13(3), 725-728.
182. Sevov, M.; Elfineh, L.; Cavelier, L.B. Resveratrol regulates the expression of LXR-alpha in human macrophages. Biochem. Biophys. Res. Commun., 2006, 348(3), 1047-1054.
183. Chen, S.; Li, Z.; Li, W.; Shan, Z.; Zhu, W. Resveratrol inhibits cell differentiation in 3T3-L1 adipocytes via activation of AMPK. Can. J. Physiol. Pharmacol., 2011, 89(11), 793-799.
184. Berrougui, H.; Grenier, G.; Loued, S.; Drouin, G.; Khalil, A. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis, 2009, 207(2), 420-427.
185. Rius, C.; Abu-Taha, M.; Hermenegildo, C.; Piqueras, L.; Cerda-Nicolas, J.M.; Issekutz, A.C.; Estan, L.; Cortijo, J.; Morcillo, E.J.; Orallo, F.; Sanz, M.J. Trans-but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-kappaB activation and peroxisome proliferator-activated receptor-gamma upregulation. J. Immunol., 2010, 185(6), 3718-3727.
186. Voloshyna, I.; Hai, O.; Littlefield, M.J.; Carsons, S.; Reiss, A.B. Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARgamma and adenosine. Eur. J. Pharmacol., 2013, 698(1-3), 299-309.
187. Rosenblat, M.; Hayek, T.; Aviram, M. Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Atherosclerosis, 2006, 187(2), 363-371.
188. Kaplan, M.; Hayek, T.; Raz, A.; Coleman, R.; Dornfeld, L.; Vaya, J.; Aviram, M. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J. Nutrition, 2001, 131(8), 2082-2089.
189. Aviram, M.; Dornfeld, L.; Rosenblat, M.; Volkova, N.; Kaplan, M.; Coleman, R.; Hayek, T.; Presser, D.; Fuhrman, B. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J. Clin. Nutr., 2000, 71(5), 1062-1076.
190. Lou-Bonafonte, J.M.; Arnal, C.; Navarro, M.A.; Osada, J. Efficacy of bioactive compounds from extra virgin olive oil to modulate atherosclerosis development. Mol. Nutr. Food Res., 2012, 56(7), 1043-1057.
191. Loued, S.; Berrougui, H.; Componova, P.; Ikhlef, S.; Helal, O.; Khalil, A. Extra-virgin olive oil consumption reduces the agerelated decrease in HDL and paraoxonase 1 anti-inflammatory activities. British J. Nutr., 2013, 110(7), 1272-1284.
192. Rosenblat, M.; Volkova, N.; Coleman, R.; Almagor, Y.; Aviram, M. Antiatherogenicity of extra virgin olive oil and its enrichment with green tea polyphenols in the atherosclerotic apolipoprotein-Edeficient mice: enhanced macrophage cholesterol efflux. J. Nutr. Biochem., 2008, 19(8), 514-523.
193. Helal, O.; Berrougui, H.; Loued, S.; Khalil, A. Extra-virgin olive oil consumption improves the capacity of HDL to mediate cholesterol efflux and increases ABCA1 and ABCG1 expression in human macrophages. Brit. J. Nutr., 2013, 109(10), 1844-1855.
194. Zhao, J.F.; Ching, L.C.; Huang, Y.C.; Chen, C.Y.; Chiang, A.N.; Kou, Y.R.; Shyue, S.K.; Lee, T.S. Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis. Mol. Nutr. Food Res., 2012, 56(5), 691-701.
195. Ramirez-Bosca, A.; Soler, A.; Carrion, M.A.; Diaz-Alperi, J.; Bernd, A.; Quintanilla, C.; Quintanilla Almagro, E.; Miquel, J. An hydroalcoholic extract of curcuma longa lowers the apo B/apo A ratio. Implications for atherogenesis prevention. Mech. Ageing Dev., 2000, 119(1-2), 41-47.
196. Park, S.H.; Kim, J.L.; Lee, E.S.; Han, S.Y.; Gong, J.H.; Kang, M.K.; Kang, Y.H. Dietary ellagic acid attenuates oxidized LDL uptake and stimulates cholesterol efflux in murine macrophages. J. Nutr., 2011, 141(11), 1931-1937.
197. Palozza, P.; Simone, R.; Catalano, A.; Parrone, N.; Monego, G.; Ranelletti, F.O. Lycopene regulation of cholesterol synthesis and efflux in human macrophages. J. Nutr. Biochem., 2011, 22(10), 971-978.
198. Yan, J.; Zhao, Y.; Zhao, B. Green tea catechins prevent obesity through modulation of peroxisome proliferator-activated receptors. Sci. China Life Sci., 2013, 56(9), 804-810.
199. Baba, S.; Natsume, M.; Yasuda, A.; Nakamura, Y.; Tamura, T.; Osakabe, N.; Kanegae, M.; Kondo, K. Plasma LDL and HDL cholesterol and oxidized LDL concentrations are altered in normoand hypercholesterolemic humans after intake of different levels of cocoa powder. J. Nutr., 2007, 137(6), 1436-1441.
200. Uto-Kondo, H.; Ayaori, M.; Ogura, M.; Nakaya, K.; Ito, M.; Suzuki, A.; Takiguchi, S.; Yakushiji, E.; Terao, Y.; Ozasa, H.; Hisada, T.; Sasaki, M.; Ohsuzu, F.; Ikewaki, K. Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages. Circulation Res., 2010, 106(4), 779-787.
201. Lee, S.M.; Moon, J.; Cho, Y.; Chung, J.H.; Shin, M.J. Quercetin up-regulates expressions of peroxisome proliferator-activated receptor gamma, liver X receptor alpha, and ATP binding cassette transporter A1 genes and increases cholesterol efflux in human macrophage cell line. Nutr. Res., 2013, 33(2), 136-143.
202. Li, X.Y.; Kong, L.X.; Li, J.; He, H.X.; Zhou, Y.D. Kaempferol suppresses lipid accumulation in macrophages through the downregulation of cluster of differentiation 36 and the upregulation of scavenger receptor class B type I and ATP-binding cassette transporters A1 and G1. Int. J. Mol. Med., 2013, 31(2), 331-338.
203. Aizawa, K.; Inakuma, T. Dietary capsanthin, the main carotenoid in paprika (Capsicum annuum), alters plasma high-density lipoprotein-cholesterol levels and hepatic gene expression in rats. Brit. J. Nutr., 2009, 102(12), 1760-1766.
204. Blesso, C.N.; Andersen, C.J.; Bolling, B.W.; Fernandez, M.L. Egg intake improves carotenoid status by increasing plasma HDL cholesterol in adults with metabolic syndrome. Food Funct., 2013, 4(2), 213-221.
205. Lottenberg, A.M.; Bombo, R.P.; Ilha, A.; Nunes, V.S.; Nakandakare, E.R.; Quintao, E.C. Do clinical and experimental investigations support an antiatherogenic role for dietary phytosterols/stanols? IUBMB life, 2012, 64(4), 296-306.
206. Sabeva, N.S.; McPhaul, C.M.; Li, X.; Cory, T.J.; Feola, D.J.; Graf, G.A. Phytosterols differentially influence ABC transporter expression, cholesterol efflux and inflammatory cytokine secretion in macrophage foam cells. J. Nutr. Biochem., 2011, 22(8), 777-783.
207. Burillo, E.; Martin-Fuentes, P.; Mateo-Gallego, R.; Baila-Rueda, L.; Cenarro, A.; Ros, E.; Civeira, F. Omega-3 fatty acids and HDL. How do they work in the prevention of cardiovascular disease? Curr. Vasc. Pharmacol., 2012, 10(4), 432-441.
208. Burillo, E.; Mateo-Gallego, R.; Cenarro, A.; Fiddyment, S.; Bea, A.M.; Jorge, I.; Vazquez, J.; Civeira, F. Beneficial effects of omega-3 fatty acids in the proteome of high-density lipoprotein proteome. Lipid. Health Dis., 2012, 11, 116.
209. Nishimoto, T.; Pellizzon, M.A.; Aihara, M.; Stylianou, I.M.; Billheimer, J.T.; Rothblat, G.; Rader, D.J., Fish oil promotes macrophage reverse cholesterol transport in mice. Arterioscler. Thromb. Vasc. Biol., 2009, 29(10), 1502-1508.
210. Ku, C.S.; Park, Y.; Coleman, S.L.; Lee, J. Unsaturated fatty acids repress expression of ATP binding cassette transporter A1 and G1 in RAW 264.7 macrophages. J. Nutr. Biochem., 2012, 23(10), 1271-1276.
211. Ishiyama, J.; Taguchi, R.; Yamamoto, A.; Murakami, K. Palmitic acid enhances lectin-like oxidized LDL receptor (LOX-1) expression and promotes uptake of oxidized LDL in macrophage cells. Atherosclerosis, 2010, 209(1), 118-124.
212. Uehara, Y.; Engel, T.; Li, Z.; Goepfert, C.; Rust, S.; Zhou, X.; Langer, C.; Schachtrup, C.; Wiekowski, J.; Lorkowski, S.; Assmann, G.; von Eckardstein, A. Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes, 2002, 51(10), 2922-2928.
213. Shao, F.; Ford, D.A. Differential regulation of ABCA1 and macrophage cholesterol efflux by elaidic and oleic acids. Lipids, 2013, 48(8), 757-767.
214. Vallve, J.C.; Uliaque, K.; Girona, J.; Cabre, A.; Ribalta, J.; Heras, M.; Masana, L. Unsaturated fatty acids and their oxidation products stimulate CD36 gene expression in human macrophages. Atherosclerosis, 2002, 164(1), 45-56.
215. He, B.M.; Zhao, S.P.; Peng, Z.Y. Effects of cigarette smoking on HDL quantity and function: implications for atherosclerosis. J. Cell. Biochem., 2013, 114(11), 2431-2436.
216. Chelland Campbell, S.; Moffatt, R.J.; Stamford, B.A. Smoking and smoking cessation -the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis, 2008, 201(2), 225-235.
217. Nakamura, K.; Barzi, F.; Huxley, R.; Lam, T.H.; Suh, I.; Woo, J.; Kim, H.C.; Feigin, V.L.; Gu, D.; Woodward, M.; Asia Pacific Cohort Studies, C. Does cigarette smoking exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the risk of cardiovascular diseases? Heart, 2009, 95(11), 909-916.
218. Imamura, H.; Teshima, K.; Miyamoto, N.; Shirota, T. Cigarette smoking, high-density lipoprotein cholesterol subfractions, and lecithin: cholesterol acyltransferase in young women. Metabolism, 2002, 51(10), 1313-1316.
219. Garrison, R.J.; Kannel, W.B.; Feinleib, M.; Castelli, W.P.; McNamara, P.M.; Padgett, S.J. Cigarette smoking and HDL cholesterol: the Framingham offspring study. Atherosclerosis, 1978, 30(1), 17-25.
220. Maeda, K.; Noguchi, Y.; Fukui, T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a metaanalysis. Prev. Med., 2003, 37(4), 283-290.
221. Dullaart, R.P.; Hoogenberg, K.; Dikkeschei, B.D.; van Tol, A. Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscl. Thromb., 1994, 14(10), 1581-1585.
222. Kong, C.; Nimmo, L.; Elatrozy, T.; Anyaoku, V.; Hughes, C.; Robinson, S.; Richmond, W.; Elkeles, R.S. Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes. Atherosclerosis, 2001, 156(2), 373-378.
223. Ueyama, K.; Yokode, M.; Arai, H.; Nagano, Y.; Li, Z.X.; Cho, M.; Kita, T. Cholesterol efflux effect of high density lipoprotein is impaired by whole cigarette smoke extracts through lipid peroxidation. Free Radic. Biol. Med., 1998, 24(1), 182-190.
224. "Whole mummy" scans confirm ancient atherosclerosis. BMJ, 2013, 346, f1591.
225. Rimm, E.B.; Williams, P.; Fosher, K.; Criqui, M.; Stampfer, M.J. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ, 1999, 319(7224), 1523-1528.
226. Liisanantti, M.K.; Savolainen, M.J. Phosphatidylethanol mediates its effects on the vascular endothelial growth factor via HDL receptor in endothelial cells. Alcohol. Clin. Exp. Res., 2009, 33(2), 283-288.
227. Corella, D.; Portoles, O.; Arriola, L.; Chirlaque, M.D.; Barrricarte, A.; Frances, F.; Huerta, J.M.; Larranaga, N.; Martinez, C.; Martinez-Camblor, P.; Molina, E.; Navarro, C.; Quiros, J.R.; Rodriguez, L.; Sanchez, M.J.; Ros, E.; Sala, N.; Gonzalez, C.A.; Moreno-Iribas, C. Saturated fat intake and alcohol consumption modulate the association between the APOE polymorphism and risk of future coronary heart disease: a nested case-control study in the Spanish EPIC cohort. J. Nutr. Biochem., 2011, 22(5), 487-494.
228. Volcik, K.A.; Ballantyne, C.M.; Fuchs, F.D.; Sharrett, A.R.; Boerwinkle, E. Relationship of alcohol consumption and type of alcoholic beverage consumed with plasma lipid levels: differences between Whites and African Americans of the ARIC study. Ann. Epidemiol., 2008, 18(2), 101-107.
229. Yin, R.X.; Li, Y.Y.; Liu, W.Y.; Zhang, L.; Wu, J.Z. Interactions of the apolipoprotein A5 gene polymorphisms and alcohol consumption on serum lipid levels. PloS One, 2011, 6(3), e17954.
230. Baik, I.; Lee, S.; Kim, S.H.; Shin, C. A lipoprotein lipase gene polymorphism interacts with consumption of alcohol and unsaturated fat to modulate serum HDL-cholesterol concentrations. J. Nutr., 2013, 143(10), 1618-1625.
231. Marmillot, P.; Munoz, J.; Patel, S.; Garige, M.; Rosse, R.B.; Lakshman, M.R. Long-term ethanol consumption impairs reverse cholesterol transport function of high-density lipoproteins by depleting high-density lipoprotein sphingomyelin both in rats and in humans. Metabolism, 2007, 56(7), 947-953.
232. Zhang, B.; Kawachi, E.; Miura, S.; Uehara, Y.; Matsunaga, A.; Kuroki, M.; Saku, K. Therapeutic approaches to the regulation of metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise. Circ. J., 2013, 77(11), 2651-2663.
233. Petitt, D.S.; Cureton, K.J. Effects of prior exercise on postprandial lipemia: a quantitative review. Metabolism, 2003, 52(4), 418-424.
234. Trejo-Gutierrez, J.F.; Fletcher, G. Impact of exercise on blood lipids and lipoproteins. J. Clin. Lipidol., 2007, 1(3), 175-181.
235. Oravec, S.; Dukat, A.; Gavornik, P.; Kucera, M.; Gruber, K.; Gaspar, L.; Rizzo, M.; Toth, P.P.; Mikhailidis, D.P.; Banach, M. Atherogenic versus non-atherogenic lipoprotein profiles in healthy individuals. Is there a need to change our approach to diagnosing dyslipidemia? Curr. Med. Chem., 2014. [Epub ahead of print].
236. Roberts, C.K.; Katiraie, M.; Croymans, D.M.; Yang, O.O.; Kelesidis, T. Untrained young men have dysfunctional HDL compared with strength-trained men irrespective of body weight status. J. Appl. Physiol., 2013, 115(7), 1043-1049.
237. Serban, C.; Muntean, D.; Mikhailids, D.P.; Toth, P.P.; Banach, M. Dysfunctional HDL: The journey from savior to slayer. Clin. Lipidol., 2014, 9(1), 49-59.
238. Barylski, M.; Toth, P.P.; Nikolic, D.; Banach, M.; Rizzo, M.; Montalto, G. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract. Res. Clin. Endocrinol. Metab., 2014, 28(3), 453-461.
239. Toth, P.P.; Barylski, M.; Nikolic, D.; Rizzo, M.; Montalto, G.; Banach, M. Should low high-density lipoprotein cholesterol (HDLC) be treated? Best Pract. Res. Clin. Endocrinol. Metab., 2014, doi: 10.1016/j.beem.2013.1011.1002.